Horizon Therapeutics Public Limited Company (HZNP) — Business segments and KPIs
Revenue by business segment and geography for Horizon Therapeutics Public Limited Company, with year-over-year trends.
FY 2022
| Segment | Revenue | % of total |
|---|---|---|
| Revenue by product | ||
| T E P E Z Z A | 1.97B | 56.4% |
| K R Y S T E X X A | 716.17M | 20.5% |
| R A V I C T I | 325.65M | 9.3% |
| P R O C Y S B I | 209.99M | 6.0% |
| Actimmune | 126.08M | 3.6% |
| P E N N S A I D Two Percent | 73.77M | 2.1% |
| R A Y O S | 41.88M | 1.2% |
| U P L I Z N A | 11.20M | 0.3% |
| B U P H E N Y L | 7.33M | 0.2% |
| D U E X I S Product | 4.90M | 0.1% |
| Vimovo | 1.85M | 0.1% |
| Q U I N S A I R | 1.08M | 0.0% |
| Revenue by region | ||
| UNITED STATES | 3.59B | 98.9% |
| Non-US | 39.53M | 1.1% |